Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Diagnostic accuracy of thirteen COVID-19 (SARS-CoV-2) rapid antigen self-tests with very high sensitivity approved for home use in Australia

Edwin A. Shores,1,2 Jamie Berry1,2
1 Advanced Neuropsychological Treatment Services, Private Practice, Sydney, New South Wales
2 Department of Psychology, Macquarie University, Sydney, New South Wales

We are concerned that the approved rapid antigen tests (RATs) used in Australia to detect SARS-CoV-2, which causes COVID-19 infection, are being used for a purpose for which they were not intended. We are also concerned that there is a lack of understanding of the role that disease prevalence has on the accuracy of the results of screening tests.

The Australian Government Department of Health Therapeutic Goods Administration (TGA) had listed 32 approved rapid antigen self-tests (RATs) (some of which appear to be duplicates) for home use by the end of February 2022.1 Information on different tests for COVID-19 and how they help understand infectiousness is provided by the United States Food and Drug Association (FDA).2 The Australian TGA has provided information on the clinical sensitivity of each test and identified 13 of these as having ‘very high’ sensitivity (i.e. >95%). Level of sensitivity is said to have been based on the proportion of individuals that produced a positive test result using a COVID-19 RAT, in comparison with a positive result that was obtained using a more sensitive laboratory polymerase chain reaction (PCR) test. However, it is notable that no information is provided on positive and negative predictive values, either by the TGA or any of the manufacturers. Such information would be necessary to provide estimates of diagnostic accuracy under conditions of differing prevalence or pre-test probability rates. We acknowledge that the first stage in accuracy studies is to determine test sensitivity and specificity because this indicates how well the test works with known positive and negative samples. We also note from the manufacturers’ documentation the intended use of RATs is to detect SARS-CoV-2, which causes COVID-19, with specimens collected from symptomatic individuals who are suspected of being infected with COVID-19 within the first seven days of symptom onset. Nevertheless, RATs are being used in Australia by asymptomatic individuals with no known epidemiological links to COVID-19 such as, for example, those wishing to travel, enter educational facilities, visit aged care residences, attend family gatherings or return to places of employment. These asymptomatic individuals have been led to believe a one-off screening test with a RAT will accurately identify SARS-CoV-2, which causes COVID-19 infection.

We analysed the top 13 tests utilising Bayes’ Rule with the sensitivity and specificity data provided by the test manufacturers to obtain estimates of the positive and negative predictive value of their tests, assuming the prevalence of active COVID-19 cases at both 1% and 3% in the community. There are differing methods of calculating prevalence rates depending upon the unique circumstances of the person being tested.3

As we were interested in the interpretation of a RAT result for a random fully vaccinated asymptomatic individual with no close contacts or other risk factors for COVID-19, we estimated the population point prevalence rate at the peak of the Omicron wave in Australia in mid-January 2022 to have been around 3%. This was based on the total number of active cases at that time as a percentage of the population.4 As of the beginning of March 2022 the estimated point prevalence decreased to below 1% (allowance for under-reporting would likely be necessary).

There were marked discrepancies between the 13 “very high” sensitivity tests, with positive predictive values ranging from 38% to 100% when prevalence is at 1% and from 65% to 100% when prevalence is at 3%. Figure 1 shows the positive predictive values and numerous instances of wide 95% confidence intervals. Four of the RATs were reported by the manufacturers to have

![Figure 1: Comparison of the positive predictive values of 13 rapid antigen tests approved by the Australian TGA under different prevalence rates.](image)

**Note:**

A = Rapid SARS-CoV-2 Antigen Test Card Self-Test; B = Panbio™ Self-Test COVID-19 Antigen; C = OnSite® COVID-19 Ag Self Test; D = Flowflex OnSite® COVID-19 Ag Self Test; E = Cellife/Medriva COVID-19 Antigen Test; F = Gardian T3 COVID-19 SARS-CoV-2 Antigen Saliva Self-Test; G = Alltest SARS-CoV-2 Antigen Rapid Test (Nasal Swab); H = Genie™ COVID-19 Ag Saliva Test; I = Veritor COVID-19 Antigen Saliva Test; J = Alere NovaTec Coronavirus (SARS-CoV-2) Antigen Rapid Test Device (Nasal Swab); K = Clungene COVID-19 Antigen Rapid Test (For Self-testing); L = LUNAR® Novel Coronavirus (COVID-19) Antigen Test Kit (Colloidal Gold) For self-testing with nasal swab specimens; M = Growell COVID-19 Ag Rapid Saliva Test Device (Self Test)

The authors have stated they have no conflicts of interest.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

722

Australian and New Zealand Journal of Public Health 2022 vol. 46 no. 5

© 2022 The Authors
had zero false positives, which produced positive predictive values of 100%. Negative predictive values for all 13 tests at both 1% and 3% prevalence were uniformly high at 99%.

The numerous low positive predictive values and wide confidence intervals present a challenge to accurate test interpretation on a one-off basis for home use. This would be particularly true for low-risk asymptomatic individuals who are fully vaccinated, with no history of close contacts or other risk factors for COVID-19. A review and meta-analysis of a large number of international independent studies showed the pooled sensitivity and specificity values for RATs from asymptomatic samples to be 56.8% and 99.1% respectively. Using the metrics from this meta-analysis would produce positive predictive values that are considerably lower than those we have calculated. This would suggest that the metrics provided by the manufacturers are likely to be over-estimates. It is also unlikely that in real-world conditions RATs would produce zero false positives.

We support the existing recommendation for using imperfect tests to make clinical decisions. In addition, careful consideration of confidence intervals is essential. RATs that have positive predictive values at or below chance, or confidence intervals that include chance level, should not be relied upon for one-off testing in low-risk individuals. Chance in this context is a posterior probability of 50%, that is, only a 50% chance of being SARS-CoV-2 positive when obtaining a positive RAT result.

There is clear evidence of vastly differing diagnostic accuracy in the 13 approved RATs with “very high” sensitivity. It is likely that many of those lower ranked tests that the TGA has deemed as having “high” sensitivity and those having “acceptable” sensitivity will be found to have unacceptably low diagnostic accuracy. Government and health officials as well as the lay public who will be using these tests, even when used for the purpose for which they were intended, especially under conditions of low prevalence, should be cognisant of the nuances in their interpretation.

References
1. Australian Therapeutic Goods Administration. COVID-19 Rapid Antigen Self-tests that are Approved in Australia [Internet]. Canberra (AUST): Australian Government Department of Health and Aged Care; 2022 [cited 2022 Feb 28]. Available from: https://www.tga.gov.au/covid-19-rapid-antigen-self-tests-are-approved-australia
2. United States Food & Drug Association. COVID-19 Test Basics. Washington (DC): U.S. Department of Health and Human Services; 2022. [cited 2022 May 10]. Available from: https://www.fda.gov/consumers/consumer-updates/covid-19-test-basics
3. Watson J, Whiting PF, Brush JE. Interpreting a covid-19 test result. BMJ. 2020;369:m1808.
4. Australian Government Department of Health and Aged Care. Coronavirus (COVID-19) Case Numbers and Statistics [Internet]. Canberra (AUST): Government of Australia; 2022 [cited 2022 Mar 2]. Available from: https://www.health.gov.au/health-alerts/covid-19/case-numbers-and-statistics
5. MedCalc: Statistical Software. Version 20.027. Ostend (BEL): MedCalc Software; 2022.
6. Brümmer LE, Katzenschlager S, McGrath S, Schmitz S, et al. Accuracy of rapid point-of-care antigen-based diagnostics for SARS-CoV-2: An updated systematic review and meta-analysis with meta regression analyzing influencing factors. PLoS Med. 2022;19(5):e1004011.
7. Bell KJ, Stanaway FF, Irwig LM, Horvath AR, Teixeira-Pinto A, Loy C. How to use imperfect tests for COVID-19 (SARS-CoV-2) to make clinical decisions. Med J Aust. 2021;214(2):69-73.e1.

Correspondence to: Adjunct Professor E. A. Shores, School of Psychological Sciences, Faculty of Medicine, Health and Human Sciences, Macquarie University, North Ryde NSW 2109; e-mail: arthur.shores@mq.edu.au